Ischemic Stroke Clinical Trial
Official title:
Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke Prevalence and Characteristics as Measured by CT Angiography, Echocardiography and Biomarkers
The specific objectives of this thesis are in a cohort of patients with an acute ischemic
stroke,
1. To establish the degree of coronary arteriosclerosis.
2. To describe left ventricular systolic and diastolic function in relation to changes of
NT-proBNP.
Background:
Stroke and myocardial infarction are leading causes of death and disability in the
industrialized countries. Multiple interactions exist between the various forms of
cardiovascular and cerebrovascular diseases and several risk factors for the development of
stroke and major cardiovascular diseases are similar, as emphasized by the recent
publication of a common set of guidelines for the primary prevention of both. Following
myocardial infarction the stroke incidence is markedly increased, particular early after
myocardial infarction. Additionally, non-stroke cardiovascular disease, especially coronary
artery disease, is the main cause of long-term mortality in patients surviving
cerebrovascular diseases. The history of ischemic heart disease in stroke patients is often
unreliable because of cognitive and language impairments or simply because ischemic heart
disease is asymptomatic. For at least 25 years myocardial damage has repeatedly been
proposed as a consequence of an acute stroke, i.e. being neuromediated. Most prior studies
were performed in patients with subarachnoid hemorrhage, and consequently only limited data
regarding ischemic stroke, the most common cerebrovascular ailment, are available. Recently
it has been demonstrated that highly sensitive and specific markers for the detection of
myocardial necrosis, i.e., cardiac troponins, may be elevated in 0 % - 34 % of patients with
ischemic stroke. However, the majority of the studies conducted have not sufficiently
evaluated coexisting coronary artery disease. The neuromediated theory has been supported in
patients with subarachnoid hemorrhage and elevated troponin levels due to lack of
significant obstructive coronary artery disease evaluated by coronary angiograms. Little is
known about a conceivable cause-effect relationship between acute ischemic stroke and
myocardial necrosis, i.e., neuromediation, or if the elevated levels of troponin are caused
by direct cardiac damage, i.e., AMI.
Recently, several reports have demonstrated that levels of natriuretic peptides are
increased in patients with acute ischemic stroke. The hormone Brain Natriuretic Peptide
(BNP) and its split product (NT-proBNP) derives predominantly from the myocardium and is
processed as a response to stretch of cardiomyocytes and hemodynamic stress. The mechanism
of elevated levels of NT-proBNP in the setting of acute ischemic stroke is unknown.
Myocardial ischemia is known to cause release of NT-proBNP. Accordingly, levels of NT-proBNP
are higher in acute ischemic stroke patients with ST-segment depression on 12-lead ECG than
in those without. However, it is unknown whether levels of NT-proBNP are correlated to
coronary arteriosclerosis and left ventricle function in patients with acute ischemic
stroke.
The current gold standard for the detection of atherosclerotic coronary artery disease
(CAD), invasive coronary angiography (CAG), allows direct visualization of the coronary
artery lumen. Inconvenience to patients and a small but not negligible risk of complications
related to CAG have prompted an intensive search for alternative, reliable non-invasive
means of coronary artery visualisation. Standard non-invasive methods such as stress testing
lack sufficient sensitivity in detecting significant CAD. Over the last decade multislice
computed tomography (MSCT) has emerged as a promising non-invasive method in the assessment
of CAD. Previous studies have convincingly demonstrated a very high negative predictive
value of MSCT coronary angiography (CTA) with CAG as the reference. Thus, a normal CTA seems
to allow the clinician to rule out the presence of hemodynamic relevant coronary artery
stenoses with a high degree of reliability. In addition to detecting significant coronary
artery stenosis, recent focus has been on visualising and characterising coronary artery
plaques. Both necropsy and coronary intravascular ultrasound (IVUS) studies have shown that
"normal" vessels at CAG may in fact contain a significant amount of atherosclerotic plaques.
Independent of the degree of coronary artery stenosis, some plaques may be at increased risk
of erosion or rupture. The latter, unstable plaques are thought to trigger acute coronary
ischemic events. Accordingly, the release of troponins, NT-proBNP and ECG changes observed
in these patients could be due to CAD. So far serial investigation of CAD has never been
performed in patients with acute ischemic stroke.
Objective:
The specific objectives of this thesis are in a cohort of patients with an acute ischemic
stroke,
1. To establish the degree of coronary arteriosclerosis.
2. To describe left ventricular systolic and diastolic function in relation to changes of
NT-proBNP.
Inclusion Criteria:
1. Age ≥ 18 years old
2. Symptoms suggestive of an acute ischemic stroke
3. Informed consent
Exclusion Criteria:
1. Present intracerebral or subarachnoid haemorrhage
2. Present intracerebral vascular malformation
3. Present transient ischemic attack
4. Prior coronary bypass surgery or percutaneous coronary intervention
5. Pacemaker
6. Allergy to contrast
7. Lack of cooperation
Clinical evaluation:
All patients included in the study will have a computed tomography scan performed at the
time of admission. The patients included undergo a baseline clinical evaluation, a
structured interview and examination of medical records focusing at
- Hypertension
- Dyslipidemia
- Diabetes mellitus
- Smoking
- Alcohol consumption
- Medication
- Atrial fibrillation
- Ischemic heart disease
- Angina Pectoris (CCS classification)
- Heart failure (NYHA- and KILLIP-classification)
- Peripheral Arterial Occlusive Disease
Electrocardiography:
A 12-lead resting ECG is obtained immediately on admission and up to each of the following
five days in the morning. The 12-lead resting ECGs were recorded in the supine position with
a paper speed of 25 mm/s. All ECGs are interpreted by two experienced cardiologist under
blinded conditions. The ECG findings of interest in this thesis are horizontal or
downsloping ST-segment depression ≥0.1 mV, T-wave inversion ≥0.1 mV in two or more
contiguous leads, and ST-segment elevation ≥0.2 mV in leads V1-3; ST-elevation ≥0.1 mV in
other leads.
Holter monitoring:
Holter 24-hour ECG recordings are performed with Reynolds Medical Tracker 3 and a Pathfinder
700 (Reynolds Medical Limited, England) for analysis. An ischemic episode is defined as ≥0.1
mV of horizontal or downsloping ST-segment depression compared to baseline, measured 80 ms
after the J-point. An episode of ST-segment depression has to last ≥2 minutes in order to
count and two episodes have to be separated by at least two minutes. In patients with
resting ST-segment depression additional ≥0.1 mV ST-segment depression has to be present.
Every episode of ST-segment deviation is verified by ECG printouts (25 mm/s). Furthermore,
Holter monitoring will be analyzed for occurrence of atrial arrhythmias. Evaluation of
ischemic and arrhythmias episodes is interpreted visually by two cardiologist blinded to
other patient characteristics.
Blood Sampling:
Blood samples are drawn immediately on admission and up to each of the following five days
in the morning. Specimens for NT-proBNP, troponin T and I, CK-MB, myeloperoxidase, oxidated
low-density lipoprotein, osteoprotegerin are collected. All analyses are performed at the
Department of Clinical Biochemistry, Vejle Hospital.
Echocardiography:
Doppler echocardiography will be performed as soon as the patient condition allows.
Examinations will be performed on a GE medical Vivid 7 ultrasound machine. Images will be
obtained from the parasternal and apical windows. M-mode recordings will be done in the
parasternal long-axis view. Pulsed Doppler measurements of mitral inflow will be obtained
with the transducer in the apical four-chamber view, with a 1-2 mm Doppler sample volume
placed between the tips of mitral leaflets during diastole. Tissue Doppler imaging of the
mitral annulus will be obtained from the apical 4-chamber view with a 1.5-mm sample volume
placed at the medial mitral annulus. All Doppler echocardiographic examinations are done
with horizontal sweep set to 100 mm/s. At least 3-5 cardiac cycles will be measured. Finally
color coded real time tissue Doppler images will be acquired in the apical windows.
- End-systolic, end-diastolic volume and ejection fraction will be calculated according
to the Simpson modified biplane method.
- LV mass will be estimated using the recommendations of the American Society of
Echocardiography.
- Maximal left atrial volume will be measured at end-systole with the use of two
orthogonal apical views.
- From the pulsed wave mitral inflow signal, peak E wave velocity, peak A wave velocity,
and mitral E-wave deceleration time will be measured. From pulsed wave Doppler
recording of LV outflow ejection time will be recorded. From these recordings Tei index
will be assessed.
- From peak tricuspid regurgitant velocity and size of inferior v. cava pulmonary
arterial systolic pressure will be estimated.
- From the tissue Doppler assessment of the medial mitral annulus early (E') diastolic
velocity will be recorded. Diastolic function will be graded in grades 0-3 and
diastolic E/e' ratio calculated.
- From color coded tissue Doppler images systolic longitudinal fibre shortening will be
assessed using tissue tracking, and systolic strain will be assessed on a regional
basis.
Multislice computed tomography coronary angiography:
Examinations are performed at the Department of Cardiology, Vejle Hospital with dual source
CT (DSCT) scanner technology (Siemens Definition; Forcheim, Germany). Tube voltage is 120kV
for both tubes, current 560 mA with modulation and full current between 25 % - 80 % of the
RR interval. Gantry rotation time is 330 msec, pitch is 0.20-0.44 according to the heart
rate. Per rotation 64 slices are generated with a collimation of 0.6 mm resulting in an
isotropic voxel size of approximately 0.6 mm. A bodyweight adapted volume of contrast agent
(Iomeron 350) is injected continuously at rate of 5 ml /sec. The scan is initiated according
to a bolus tracking protocol (aortic root attenuation level of 100 HU). Axial images are
reconstructed with 0.75 mm slice thickness, and a 0.5 mm increment using a medium sharp
kernel (B26) and retrospective ECG gating. The reconstructions are performed in 5 % steps
over the relevant part of the RR cycle using a single-segment algorithm. In case of atrial
fibrillation, data sets were reconstructed in 50 ms steps. Using a semi-automated Hounsfield
dependent algorithm, differentiation between contrast enhanced lumen, vessel wall and
atherosclerotic plaques, is performed. Atherosclerotic plaques will be categorized into
calcified (>130 HU, high density plaque), non-calcified (< 60 HU, low density plaque), and
mixed-type plaques (60-130 HU, intermediate density plaque), respectively. According to an
American Heart Association 17 segmental coronary artery model, stenoses > 50 % or > 75 % are
registered. Main coronary vessels (left main, left anterior descending artery, circumflex,
and the right coronary artery) and side branches with a lumen diameter > 1, 5 mm are
analysed. Image quality will be assessed as good (no artefacts related to motion,
calcification or noise), satisfactory (artefacts present, but assessment of artery stenosis
possible), or unsatisfactory (artefacts compromising the evaluation of artery stenosis).
Images are analysed by two independent observes without knowledge of the patient history.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |